PF 5190457
Alternative Names: PF-05190457; PF-5190457Latest Information Update: 02 Oct 2021
At a glance
- Originator Pfizer
- Class Antihyperglycaemics
- Mechanism of Action Ghrelin inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in Belgium (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in Singapore (PO)
- 18 Apr 2012 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (PO)